Mizuho assumed coverage on shares of Regenxbio (NASDAQ:RGNX) in a report released on Monday, February 12th, MarketBeat Ratings reports. The firm set a “neutral” rating and a $28.00 price target on the biotechnology company’s stock. Mizuho’s price objective indicates a potential upside of 4.28% from the company’s current price.
Other analysts have also recently issued research reports about the stock. BidaskClub cut shares of Regenxbio from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. TheStreet cut shares of Regenxbio from a “c” rating to a “d+” rating in a research note on Tuesday, November 28th. Chardan Capital upped their price target on shares of Regenxbio from $75.00 to $85.00 and gave the stock a “buy” rating in a research note on Thursday, November 9th. Raymond James Financial reiterated a “buy” rating on shares of Regenxbio in a research note on Friday, January 5th. Finally, ValuEngine cut shares of Regenxbio from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. Regenxbio currently has a consensus rating of “Buy” and an average target price of $40.63.
Shares of Regenxbio (RGNX) traded up $0.05 during mid-day trading on Monday, hitting $26.85. 148,395 shares of the stock were exchanged, compared to its average volume of 438,790. Regenxbio has a 1 year low of $16.30 and a 1 year high of $36.45. The company has a market cap of $836.25 and a PE ratio of -9.91.
In other news, CFO Vittal Vasista sold 5,000 shares of the company’s stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $30.00, for a total transaction of $150,000.00. Following the completion of the sale, the chief financial officer now owns 87,277 shares of the company’s stock, valued at approximately $2,618,310. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Curran Simpson sold 30,000 shares of the stock in a transaction that occurred on Friday, December 22nd. The stock was sold at an average price of $33.03, for a total transaction of $990,900.00. Following the completion of the sale, the senior vice president now directly owns 69,500 shares of the company’s stock, valued at $2,295,585. The disclosure for this sale can be found here. Insiders have sold a total of 84,000 shares of company stock worth $2,601,996 in the last 90 days. Company insiders own 17.00% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in RGNX. Legal & General Group Plc increased its holdings in Regenxbio by 41.4% in the 2nd quarter. Legal & General Group Plc now owns 6,870 shares of the biotechnology company’s stock worth $137,000 after acquiring an additional 2,011 shares in the last quarter. Ardsley Advisory Partners purchased a new stake in Regenxbio in the 2nd quarter worth approximately $197,000. Voya Investment Management LLC purchased a new stake in Regenxbio in the 2nd quarter worth approximately $249,000. Teacher Retirement System of Texas purchased a new stake in Regenxbio in the 4th quarter worth approximately $302,000. Finally, Wells Fargo & Company MN increased its holdings in Regenxbio by 1.1% in the 2nd quarter. Wells Fargo & Company MN now owns 16,209 shares of the biotechnology company’s stock worth $320,000 after acquiring an additional 175 shares in the last quarter. 66.85% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This article was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://ledgergazette.com/2018/02/20/regenxbio-rgnx-coverage-initiated-at-mizuho.html.
Regenxbio Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.